Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,822.12
    +480.14 (+0.94%)
     
  • CMC Crypto 200

    1,381.21
    +68.58 (+5.22%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Medtronic Earnings, Revenue Beat in Q2

Medtronic Earnings, Revenue Beat in Q2
Medtronic Earnings, Revenue Beat in Q2

Investing.com - Medtronic reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.

The firm reported earnings per share of $1.31 on revenue of $7.71B. Analysts polled by Investing.com forecast EPS of $1.28 on revenue of $7.66B. That compared to EPS of $1.22 on revenue of $7.5B in the same period a year earlier. The company had reported EPS of $1.26 on revenue of $7.49B in the previous quarter.

Medtronic follows other major Healthcare sector earnings this month

On October 29, Merck&Co reported third quarter EPS of $1.51 on revenue of $12.4B, compared to forecasts of EPS of $1.24 on revenue of $11.64B.

ADVERTISEMENT

Novartis ADR earnings beat analysts' expectations on October 22, with third quarter EPS of $1.41 on revenue of $12.17B. Investing.com analysts expected EPS of $1.32 on revenue of $11.7B

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Sustainable investors face squeeze as larger firms move in

Return of short-selling bans: market protection or 'war against truth'?

How to make the most of a zero-commission world